(1) POSSESSION, USE AND CALIBRATION OF
INSTRUMENTS TO MEASURE THE ACTIVITY OF UNSEALED RADIOACTIVE MATERIALS.
(a) For direct measurements performed under
sub. (3), a licensee shall possess and use instrumentation to measure the
activity of unsealed radioactive materials prior to administration of unsealed
radioactive materials to each patient or human research subject.
(b) A licensee shall calibrate the
instrumentation required in par. (a) according to nationally recognized
standards or the manufacturer's instructions.
(c) A licensee shall retain a record of each
instrument calibration required by this subsection under s.
DHS 157.71 (6).
(2) CALIBRATION OF
SURVEY INSTRUMENTS.
(a) A licensee shall
calibrate the survey instruments used to show compliance with this subchapter
and subch. III before first use, at a frequency not to exceed 13 months and
following any repair that will affect the calibration.
(b) A licensee shall do all the following:
1. Calibrate all scales with readings up to
10 mSv (1000 mrem) per hour with a radiation source.
2. Calibrate each scale used to show
compliance at a sufficient number of readings to determine the response
characteristics of the instrument.
3. Conspicuously note on the instrument the
date of calibration.
Note: Two separated readings on each scale or
decade are typically used for linear scale
instruments.
(c) A
licensee may not use survey instruments if the difference between the indicated
exposure rate and the calculated exposure rate is more than 20%.
(d) A licensee shall retain a record of each
survey instrument calibration under s.
DHS 157.71 (7).
(3) DETERMINATION OF DOSAGES OF UNSEALED
RADIOACTIVE MATERIAL FOR MEDICAL USE.
(a) A
licensee shall determine and record the activity of each dosage prior to
medical use.
(b) For a unit dosage,
this determination shall be made by using one of the following methods:
1. Direct measurement of
radioactivity.
2. A decay
correction, based on the measurement made by either of the following:
a. A manufacturer or preparer licensed under
s.
DHS 157.13 (4) (i) or by NRC or another agreement state.
b. An NRC or other agreement state licensee
only for use in research in accordance with an RDRC protocol or and IND
protocol accepted by FDA.
c. A PET
radioactive drug producer licensed under s.
DHS 157.13 (1) (j) or by NRC or
another agreement state.
(c) For other than unit dosages, the
determination of dosages of unsealed radioactive material shall be made through
one of the following methods:
1. Direct
measurement of radioactivity.
2. A
combination of direct measurements of radioactivity and mathematical
calculations.
3. A combination of
volumetric measurements and mathematical calculations, based on the measurement
made by a manufacturer or preparer licensed under s.
DHS 157.13 (4) (i), a PET
radioactive drug producer licensed under s.
DHS 157.13 (1) (j), or equivalent
NRC or other agreement state requirements.
(d) Unless otherwise directed by the
authorized user, a licensee may not use a dosage if the dosage differs from the
prescribed dosage by more than 20% or if the dosage does not fall within the
prescribed dosage range.
(e) A
licensee shall retain a record of the dosage determination required by this
subsection under s.
DHS 157.71 (8).
(4) AUTHORIZATION FOR CALIBRATION,
TRANSMISSION AND REFERENCE SOURCES.
(a) Any
person authorized by s.
DHS 157.13 (5) for medical use of radioactive material
may receive, possess and use any of the following radioactive material for
check, calibration, transmission and reference use:
1. A sealed source that does not exceed 1.11
GBq (30 mCi) that is manufactured and distributed by a person licensed under s.
DHS 157.13 (4) (j) or equivalent NRC or agreement state regulations or
redistributed by a person authorized to redistribute sealed sources, provided
that the redistributed sealed sources are in the original packaging and
shielding and are accompanied by the manufacturer's approved
instructions.
2. Any radioactive
material with a half-life not longer than 120 days in individual amounts not to
exceed 0.555 GBq (15 mCi).
3. Any
radioactive material with a half-life longer than 120 days in individual
amounts not to exceed the smaller of 7.4 MBq (200 microcuries) or 1000 times
the quantities in ch. DHS 157 Appendix F.
4. Technetium-99m in amounts as
needed.
5. Flourine-18 in amounts
as needed.
(b)
Radioactive material in sealed sources authorized by this subsection shall not
be used in either of the following:
2. Bundled or aggregated to create activity
greater than the maximum activity of any single sealed source authorization
under this section.
(c) A
licensee using calibration, transmission, and reference sources in accordance
with the requirements in this subsection need not list these sources on a
specific medical use license.
(5) REQUIREMENTS FOR POSSESSION OF SEALED
SOURCES AND BRACHYTHERAPY SOURCES.
(a) A
licensee in possession of any sealed source or brachytherapy source shall
follow the radiation safety and handling instructions supplied by the
manufacturer.
(b) A licensee in
possession of a sealed source shall do both the following:
1. Test the source for leakage before its
first use unless the licensee has a certificate from the supplier indicating
that the source was tested within 6 months before transfer to the
licensee.
2. Test the source for
leakage at intervals not to exceed 6 months or at other intervals approved by
the department, NRC or another agreement state in the sealed source and device
registry.
3. Test the source for
leakage at any time there is reason to suspect that the sealed source might
have been damaged or might be leaking.
(c) To satisfy the leak test requirements of
this section, a licensee shall measure the sample so that the leakage test may
detect the presence of 185 Bq (0.005 µCi) of radioactive material on the
sample.
(d) A licensee shall retain
leakage test records under s.
DHS 157.71 (9).
(e) If the leakage test reveals the presence
of 185 Bq (0.005 µCi) or more of removable contamination, a licensee
shall do both the following:
1. Immediately
withdraw the sealed source from use and store, dispose or cause it to be
repaired under the requirements in subchs. II and III.
2. File a report to the department within 5
working days of the leakage test as specified under s.
DHS 157.72 (3).
(f) A licensee need
not perform a leakage test on any of the following sources:
1. A source containing only radioactive
material with a half-life of less than 30 days.
2. A source containing only radioactive
material as a gas.
3. A source
containing 3.7 MBq (100 µCi) or less of beta or gamma-emitting material
or 0.37 MBq (10 µCi) or less of alpha-emitting material.
4. A source stored and not being used. A
licensee shall, however, test each source for leakage before any use or
transfer unless it has been leakage-tested within 6 months before the date of
use or transfer.
5. Seeds of
iridium-192 encased in intact nylon ribbon.
(g) A licensee in possession of sealed
sources or brachytherapy sources, except for gamma stereotactic radiosurgery
sources, shall conduct a semi-annual physical inventory of all such sources in
its possession. A licensee shall retain each inventory record under s.
DHS 157.71 (9).
(6) LABELLING
OF VIALS AND SYRINGES. Each syringe and vial that contains a radioactive drug
containing radioactive material shall be labeled to identify the radioactive
drug. Each syringe shield and vial shield shall also be labeled unless the
label on the syringe or vial is visible when shielded.
(7) SURVEYS FOR AMBIENT RADIATION EXPOSURE
RATE.
(a) Except as provided in par. (b), a
licensee shall survey with a radiation detection survey instrument at the end
of each day of use all areas where radioactive drugs containing radioactive
material requiring a written directive were prepared for use or
administered.
(b) A licensee need
not perform the surveys required under par. (a) in an area where patients or
human research subjects are confined when the patients or human research
subjects cannot be released under sub. (8).
(c) A licensee shall retain a record of each
survey under s.
DHS 157.71 (10).
(8) RELEASE OF INDIVIDUALS CONTAINING
RADIOACTIVE DRUGS OR IMPLANTS CONTAINING RADIOACTIVE MATERIAL.
(a) A licensee may authorize the release from
its control of any person who has been administered radioactive drugs or
implants containing radioactive material if the total effective dose equivalent
to any other person from exposure to the released individual is not likely to
exceed 5 mSv (0.5 rem).
Note: WISREG 1556, Vol. 9, Guidance for
Medical Use of Radioactive Material describes methods for calculating doses to
other individuals and contains tables of activities not likely to cause doses
exceeding 5 mSv (0.5 Rem). It is available from the following website:
http://dhs.wisconsin.gov/radiation/radioactivematerials/index.htm.
(b) A licensee shall provide the
released person or the person's parent or guardian with instructions, including
written instructions, on actions recommended to maintain doses to other persons
as low as is reasonably achievable if the total effective dose equivalent to
any other person is likely to exceed one mSv (0.1 rem). If the total effective
dose equivalent to a breast-feeding infant or child could exceed one mSv (0.1
rem) assuming there were no interruption of breast-feeding, the instructions
shall also include all the following:
1.
Guidance on the interruption or discontinuation of breast-feeding.
2. Any information on the potential
consequences of failure to follow the guidance.
(c) A licensee shall maintain a record, as
required by s.
DHS 157.71 (11), of the basis for authorizing the release of an
individual, under par. (a).
(d) A
licensee shall maintain a record of instructions provided to breast-feeding
women under par. (b) according to record retention requirements of s.
DHS 157.71 (11) (b).
(9)
PROVISION OF MOBILE MEDICAL SERVICE.
(a) A
licensee providing mobile medical service shall do all of the following:
1. Obtain a letter signed by the management
of each client for which services are rendered by the licensee that permits the
use of radioactive material at the client's address and clearly delineates the
authority and responsibility of the licensee and the client.
2. Check instruments used to measure the
activity of unsealed radioactive materials for proper function before medical
use at each client's address or on each day of use, whichever is more frequent.
The check for proper function shall include a test to verify accurate
calibration using a known radioactive source.
3. Check survey instruments for proper
operation with a dedicated check source before use at each client's
address.
4. Before leaving a
client's address, survey all areas of use to ensure compliance with the
requirements in subch. III.
(b) A mobile medical service may not have
radioactive material delivered from the manufacturer or the distributor to the
client unless the client has a license allowing possession of the radioactive
material. Radioactive material delivered to the client shall be received and
handled in conformance with the client's license.
(c) A licensee providing mobile medical
services shall retain the letter required in par. (a) 1. and the record of each
survey required in s.
DHS 157.71 (12) (b).
(10) DECAY-IN-STORAGE.
(a) A licensee may hold radioactive material
with a physical half-life of less than 120 days for decay-in-storage before
disposal without regard to its radioactivity if the licensee does both the
following:
1. Monitors radioactive material at
the surface before disposal and determines that its radioactivity cannot be
distinguished from the background radiation level with an appropriate radiation
detection survey meter set on its most sensitive scale and with no interposed
shielding.
2. Removes or
obliterates all radiation labels except for material that will be handled as
biomedical waste after it has been released.
(b) A licensee shall retain a record of each
disposal permitted under s.
DHS 157.71 (13).
Notes
Wis. Admin. Code Department of Health Services
DHS 157.62
CR 01-108: cr.
Register July 2002 No. 559, eff. - see Note at the start of the chapter;
corrections in (9) (c) and (10) (b) made under s. 13.93(2m) (b) 7, Stats.,
Register July 2002 No. 559; CR 06-021: am. (2) (a), (3) (b) 2. a., (4) (intro.)
and (8) (d) Register October 2006 No. 610, eff. 11-1-06; CR 09-062: am. (1) (b)
and (3) (c) 3., cr. (3) (b) 2. c. Register April 2010 No. 652, eff.
5-1-10.
Amended by,
correction in (4) (b) made under s.
35.17, Stats.,
Register
January 2018 No. 745, eff.
2/1/2018
Amended by, CR 22-015: r. and recr.
(4), cr. (5) (b) 3.
Register
June 2023 No. 810, eff. 7/1/2023